Add to a list

Inactive Instrument

XOMA Corp Stock Nasdaq

US98419J1079

Last Transcript: XOMA Corp

Ligand Pharmaceuticals Incorporated, XOMA Royalty Corporation - M&A Call

04-27

More transcripts

Analysts' recommendations: XOMA Corp

04-30	HC Wainwright Downgrades XOMA Royalty to Neutral From Buy, Adjusts Price Target to $39 From $97	MT
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
25-09-17	XOMA Royalty announces closing of tender offer for HilleVax	RE
25-04-17	Benchmark Initiates XOMA Royalty at Buy With $35 Price Target	MT
24-04-29	Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	MT

More recommendations

News in other languages: XOMA Corp

23-10-28	Obseva: Organon rétrocède la licence pour Ebopiprant, paiement d'étape éteint
23-10-28	Obseva: Organon gibt Lizenz für Ebopiprant zurück - Meilensteinanspruch erlischt
23-03-15	Kuros: le déploiement commercial du Magnetos a creusé le déficit en 2022
23-02-24	Obseva réduit la voilure autour de ses actifs restants
22-12-19	Obseva: la demande de retrait de sursis concordataire est acceptée

More news

Managers and Directors: XOMA Corp

Manager	Title	Age	Since
Owen Hughes CEO	Chief Executive Officer	51	2022-12-31
Jeffrey Trigilio DFI	Director of Finance/CFO	42	2026-01-11
Bradley Sitko CIO	Chief Investment Officer	45	2023-01-02

More insiders

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Companyâ€™s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Employees

Sector

Entertainment Production

More about the company

Market Cap	710M 615M 576M 526M 989M 67.73B 1.01B 6.76B 2.65B 33.9B 2.67B 2.61B 113B	P/E 2024	-15.9x	P/E 2025	18.3x
Enterprise Value	758M 657M 615M 561M 1.06B 72.34B 1.07B 7.21B 2.83B 36.21B 2.85B 2.79B 121B	EV / Sales 2024	11.4x	EV / Sales 2025	7.24x
Free-Float	98.68%	Yield 2024 *	-	Yield 2025	-

07-14	Ligand Pharmaceuticals Incorporated completed the acquisition of XOMA Royalty Corporation from a group of shareholders.	CI
07-14	Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase	MT
07-14	XOMA Royalty Corp Announces Management Changes	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P TMI Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P Global BMI Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from NASDAQ Composite Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000 Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Growth Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Value Benchmark Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Growth Benchmark Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000E Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000E Growth Benchmark	CI

07-14	XOMA Royalty : Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	PU
07-14	XOMA Royalty Announces Closing of Its Acquisition by Ligand	AQ
06-12	XOMA Royalty : Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	PU
06-12	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	AQ
04-28	XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XOMA CORP	-14.90%	-36.01%	-	-	710M
DIVERSIFIED ROYALTY CORP.	+0.66%	-2.14%	+37.13%	+61.27%	615M
FRANCHISE BRANDS PLC	+1.01%	+2.91%	+11.30%	+1.86%	385M
NEXTONE INC.	-1.67%	+14.63%	-11.91%	-13.95%	105M
MEDIALINK GROUP LIMITED	0.00%	+1.46%	-21.13%	+6.09%	51.36M
Average	-3.15%	+446.00%	+3.84%	+13.82%	289.16M
Weighted average by Cap.	-5.51%	+199.54%	+21.48%	+32.20%

	2024	2025
Net sales	28.49M 24.69M 23.11M 21.09M 39.68M 2.72B 40.35M 271M 106M 1.36B 107M 105M 4.54B	52.15M 45.19M 42.31M 38.6M 72.64M 4.97B 73.86M 496M 194M 2.49B 196M 192M 8.31B
Net income	-13.82M -11.98M -11.21M -10.23M -19.25M -1.32B -19.58M -131M -51.51M -660M -51.89M -50.76M -2.2B	31.71M 27.48M 25.73M 23.47M 44.17M 3.02B 44.92M 302M 118M 1.51B 119M 116M 5.05B
Net Debt	14.02M 12.15M 11.37M 10.37M 19.52M 1.34B 19.85M 133M 52.24M 669M 52.62M 51.48M 2.23B	48.26M 41.83M 39.16M 35.73M 67.23M 4.6B 68.36M 459M 180M 2.3B 181M 177M 7.69B

XOMA Corp Stock Nasdaq

Stocks

US98419J1079

Entertainment Production

Valuation: XOMA Corp

Latest news : XOMA Corp

Last Transcript: XOMA Corp

Analysts' recommendations: XOMA Corp

Press Releases: XOMA Corp

News in other languages: XOMA Corp

Quotes and Performance

Managers and Directors: XOMA Corp

Copyright Management

Financials

Company Profile